In summary, c-MET–centered combination therapy strategies in OS encompass a broad spectrum of interventions, including small-molecule inhibitors, non-coding RNAs, biological regulatory axes, and modulation of the tumour immune microenvironment. Here, MET is linked to neoplasm.